EMIF
In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aims to address this by developing a common Information Framework that enables improved access to these data sources, enhancement through linkage of the different sources and collection of additional new information. EMIF will focus on two specific research objectives in order to guide the development of the Information Framework: identification and evaluation of biomarkers i) of the risk for metabolic complications in obesity; ii) of Alzheimer’s Disease onset in the preclinical and prodromal phase, which in both cases will identify high-risk individuals for future intervention trials. To achieve this, a variety of data sources ranging from small-scale information-rich disease cohorts for biomarker discovery to large EHR data for population characterisation and biomarker validation will be utilised. An extreme phenotype approach will utilise the subpopulations at the extremes of a particular trait distribution using large-scale metabolomics and proteomics for biomarker evaluation. The development of the Information Framework will involve addressing data standards, semantic interoperability as well as ethics, data privacy, legal issues and the development of an IT platform for multi data sources access. The Information Framework will be designed to support the current research objectives, but more generally studies using human health data. The project consortium is a partnership between Academia and EFPIA and comprises a large number of world-renown experts in data access and linkage and the Metabolic and AD therapeutic areas, with many being involved in other related projects
Universidad Pompeu Fabra
Leibniz-Institut Fur Praventionsforschung Und Epidemiologie - Bips Gmbh
Universite Pierre Et Marie Curie - Paris 6
Pfizer Limited
The University Of Exeter
Ealing Hospital Nhs Trust
Tartu Ulikool
Universiteit Antwerpen
Helsingin Yliopisto
Agenzia Regionale Di Sanita
Cambridge Cognition Limited
The Chancellor Masters And Scholarsof The University Of Cambridge
Institut National De La Sante Et De La Recherche Medicale
The University Of Manchester
Glaxosmithkline Research And Development Ltd.
Maat France Sarl
Ucb Biopharma Srl
European Molecular Biology Laboratory
Fondazione Penta - For The Treatment And Care Of Children With Hiv Andrelated Diseases - Onlus
Genomedics S.R.L.
Teknologian Tutkimuskeskus Vtt Oy
Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina
Assistance Publique Hopitaux De Paris
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Ev
Vestische Caritas-Kliniken Gmbh
European Institute For Health Records
Kobenhavns Universitet
Amgen
F. Hoffmann-La Roche Ag
Universiteit Maastricht
Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio- Fatebenefratelli
Universitaet Leipzig
Universita Di Pisa
Universidade De Aveiro
Electrophoretics Ltd
Stichting Vumc
Boehringer Ingelheim Internationalgmbh
Vib Vzw
Societa Servizi Telematici Srl
Aarhus Universitetshospital
Karolinska Institutet
The Chancellor
Masters And Scholars Of The University Of Oxford
Erasmus Universitair Medisch Centrum Rotterdam
University College London
University Of Glasgow
University Of Leicester
Novo Nordisk A/S
Universitatsklinikum Erlangen
Institut De Recherches Internationales Servier Iris
Brighton Collaboration Foundation
Medical Research Council
Universitaet Zu Luebeck
Ita-Suomen Yliopisto
Concentris Research Management Gmbh
Synapse Research Management Partners Sl
Goeteborgs Universitet
Alzheimer Europe
King'S College London
Stichting Informatievoorziening Voor Zorg En Onderzoek
Merck Kgaa
Custodix Nv
Janssen Pharmaceutica Nv